ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1384

Comparison of the Systemic Lupus Collaborating Clinics-Damage Index Score with a Physician Global Assessment of Damage in an International Cohort of Patients with Childhood-Onset Systemic Lupus

Michael J. Holland1, Jun Ying2, Nicolino Ruperto3,4, Kasha Wiley1, Earl Silverman5 and Hermine I. Brunner1, 1Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH, 3Pediatria II, Reumatologia, Istituto Giannina Gaslini, Genoa, Italy, 4Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genoa, Italy, 5Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: measure and pediatric rheumatology, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:   Childhood-onset systemic lupus erythematosus (cSLE) is a chronic autoimmune disease, which can affect any organ system. cSLE is associated with significant morbidity, including diverse types of disease-related organ damage: up to 58% of children have apparent damage at 5 years after diagnosis. The Systemic Lupus Collaborating Clinics-Damage Index (SDI) is the only widely-used damage measure in patients with SLE (and cSLE), but was designed to list extant types of damage, not quantify severity. We sought to determine how this “listing” approach compared to a physician global assessment of disease-related damage in an international registry of cSLE patients.

Methods: The PRINTO (Pediatric Rheumatology International Trials Organization) cSLE registry includes longitudinal follow-up (mean approximately 3 years) of patients meeting revised American College of Rheumatology criteria for classification of SLE. Data from 557 patients, with a total of 1820 visits, was available for review. Data included SDI item and total scores, as well as a physician visual analog scale rating damage from 0 to 10. First, frequency of SDI summary scores was determined. The total SDI score and physician global rating of disease damage were then examined for correlation via Spearman rank-order testing. Finally, a mixed-effect model was used to determine the association of individual items with the physician damage global assessment.

Results: Out of 1820 visits, 1268 visits were assigned a SDI score of zero, while 552 (30.3%) had a non-zero score. Of non-zero scores, 331 visits received a score of one, 116 a score of two, 48 a score of three, 18 each a score of four or five, and 11 a score of six. A further 10 visits were assigned a SDI score of greater than 6. Spearman correlation of non-zero SDI scores with damage VAS was moderate at 0.496 (p value <0.0001). When visits with a SDI score of zero were included, the correlation coefficient was strong at 0.71 (p value <0.0001). Interestingly, of visits with a SDI score of zero (n=1268) 23.7% (n=301) were assigned a physician damage global greater than zero. Mixed effect analysis revealed that only 4 of the 41 SDI items were significantly associated with the physician damage global rating (Pulmonary Fibrosis, Shrinking Lung Syndrome, Chronic Pericarditis, Extensive Cutaneous Scar).

Conclusion: Our analysis revealed that a significant number of cSLE patients were found to have disease-related damage, even within the relatively limited follow-up period. It is also interesting to note the significant discrepancy between SDI scores of zero with non-zero physician global assessments, which could suggest either misunderstanding of the scale by raters, or damage items not captured by the SDI. The moderate correlation between non-zero SLICC-DI scores and the physician damage assessment suggests the need for a new or modified scale to specifically address damage severity. Finally, the lack of an association between the great majority of damage items and the physician damage assessment implies that item weightings alone would be insufficient to improve capture of damage severity.


Disclosure: M. J. Holland, NIH, 2; J. Ying, NIH, 2; N. Ruperto, BMS, GlaxoSmithKline (GSK), Hoffman-La Roche, Novartis, Pfizer, Sanofi Aventis, Schwarz Biosciences, Abbott, Francesco Angelini S.P.A., Sobi, Merck Serono, 2,AbbVie, Amgen, Biogenidec, Alter, AstraZeneca, Baxalta Biosimilars, Biogenidec, Boehringer, BMS, Celgene, CrescendoBio, EMD Serono, Hoffman-La Roche, Italfarmaco, Janssen, MedImmune, Medac, Novartis, Novo Nordisk, Pfizer, Sanofi Aventis, Servier, Takeda, 8; K. Wiley, None; E. Silverman, None; H. I. Brunner, NIH, 2.

To cite this abstract in AMA style:

Holland MJ, Ying J, Ruperto N, Wiley K, Silverman E, Brunner HI. Comparison of the Systemic Lupus Collaborating Clinics-Damage Index Score with a Physician Global Assessment of Damage in an International Cohort of Patients with Childhood-Onset Systemic Lupus [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/comparison-of-the-systemic-lupus-collaborating-clinics-damage-index-score-with-a-physician-global-assessment-of-damage-in-an-international-cohort-of-patients-with-childhood-onset-systemic-lupus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-the-systemic-lupus-collaborating-clinics-damage-index-score-with-a-physician-global-assessment-of-damage-in-an-international-cohort-of-patients-with-childhood-onset-systemic-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology